MedPath

Shenyang Xingqi Pharmaceutical Co., Ltd.

Shenyang Xingqi Pharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
Public
Established
1977-03-24
Employees
1.5K
Market Cap
-
Website
http://www.sinqi.com
Introduction

The company is a national high-tech enterprise specializing in R&D, production and sales of ophthalmic drugs. On December 8, 2016, the company was listed on the Shenzhen Stock Exchange GEM. It won the 9th Liaoning Provincial Governor's Quality Silver Award in 2022 and the 20th National Quality Award in 2023. The company leads the high-quality development of enterprises with high-quality party building, adheres to the mission of “managing health and creating light”, implements the values of “persistence, innovation, responsibility and win-win” with the vision of “becoming a globally competitive ophthalmic drug research and manufacturing enterprise”, and actively invests in the human eye health industry. The company is a professional ophthalmic drug R&D, production and sales enterprise with leading R&D technology level and wide product line coverage in China. The company's products include drugs to slow the progression of myopia in children, drugs to treat dry eye, ophthalmic anti-infective drugs, ophthalmic antiinflammatory/anti-infective drugs, pupil dilators and ciliary muscle paralysis drugs, ophthalmic non-steroidal anti-inflammatory drugs, pupil reduction drugs, and anti-glaucoma drugs. Corporate honors include: the State Intellectual Property Office recognized as a national intellectual property model enterprise, won the “9th Governor's Quality Award Silver Award of Liaoning Province”, “Liaoning May 1st Labor Award”, “2021-2023 Pharmaceutical Industry Law-abiding and Honest Enterprise”, “Provincial Green Factory”, “14th China Listed Company Investor Relations Tianma Award”, the 20th “National Quality Award”, the 19th China Listed Company Board of Directors “Excellent Board of Directors”, “2023 Biochemical and Biological Enterprise Outstanding Brand”, won the honorary title of “2023 Biochemical and Biological Enterprise Award”, and won the honorary title of Ophthalmology Science and Technology Progress Award, “Brand Enterprise List”” The “List of Most Popular Brands in Retail Pharmacies” and the company's product Erming Sodium Hyaluronate Eye Drops won the “Most Recommended Brand by Eye Health Clerk”, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

65

NMPA:65

Drug Approvals

Tafluprost Eye Drops

Product Name
他氟前列素滴眼液
Approval Number
国药准字H20253164
Approval Date
Jan 14, 2025
NMPA

Olopatadine Hydrochloride Eye Drops

Product Name
盐酸奥洛他定滴眼液
Approval Number
国药准字H20249276
Approval Date
Nov 5, 2024
NMPA

Bromfenac Sodium Eye Drops

Product Name
溴芬酸钠滴眼液
Approval Number
国药准字H20244468
Approval Date
Jul 22, 2024
NMPA

Atropine Sulfate Eye Drops

Product Name
硫酸阿托品滴眼液
Approval Number
国药准字H20243320
Approval Date
Mar 12, 2024
NMPA

Olopatadine Hydrochloride Eye Drops

Product Name
盐酸奥洛他定滴眼液
Approval Number
国药准字H20193101
Approval Date
Mar 5, 2024
NMPA

Lysozyme Eye Drops

Product Name
溶菌酶滴眼液
Approval Number
国药准字H20190023
Approval Date
Mar 5, 2024
NMPA

Compound Chondroitin Sulfate Eye Gel

Product Name
复方硫酸软骨素眼用凝胶
Approval Number
国药准字H20090118
Approval Date
Dec 26, 2023
NMPA

Gatifloxacin Eye Gel

Product Name
迪友
Approval Number
国药准字H20090161
Approval Date
Dec 26, 2023
NMPA

Sodium Hyaluronate Eye Drops

Product Name
玻璃酸钠滴眼液
Approval Number
国药准字H20234282
Approval Date
Oct 12, 2023
NMPA

Diquafosol Sodium Eye Drops

Product Name
地夸磷索钠滴眼液
Approval Number
国药准字H20233992
Approval Date
Aug 1, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.